INTRODUCTION
Prostate carcinoma (PC) is the second most diagnosed cancer in men worldwide and among leading causes of cancer-related death. It has been estimated that by 2030 there will be nearly 1.7 million new cases and half a million deaths from prostate cancer. 1 The core needle biopsy remains a crucial method for PC diagnosis. Prostate tissue expresses a wide variety of the architectural patterns some of which are difficult for interpretation. Many normal anatomical structures as seminal vessels and paraganglia, reactive and pathophysiological conditions as adenosis, atrophy, hyperplasia and metaplasia could mimic architectural and cytological features of PC. 2 These conditions require no additional treatment so recognising them correctly is of paramount importance. Immunohistochemical (IHC) markers (AMACR, p63 and 34βE12) currently recruited in PC diagnosis are of great value, but often their interpretation is controversial. Previous studies reported about 20% of cases containing adenosis, partial atrophy and post-atrophic hyperplasia that had positive AMACR expression and complete lack of expression of basal layer markers. 3, 4 In 2005 Tomlins et al. identified an emerging marker, erythroblastosis E26 rearrangement gene (ERG), which is a member of the family of genes encoding erythroblast-transformation specific transcription factors (ETS) with frequent expression in PC. A pathway of the ERG overexpression is recurrent chromosomal rearrangements after gene fusion including ERG and androgen -presenting gene TMPRSS2 (Transmembrane Protease Serine 2 gene). 5 ERG expression has been found in 50% of PC cases, but little is known about the presence and absence of this gene alteration in such prostatic lesion as adenosis, atrophy and hyperplasia. 6, 7 
AIM
The aim of this study was to investigate the expression of ERG in benign mimickers of PC in needle biopsies and find its diagnostic value separately and in combination with AMACK and 34βE12.
Introduction: Prostate carcinoma (PC) is the second most diagnosed cancer in men worldwide. Prostate tissue in needle biopsy expresses a wide variety of architectural patterns some of which are difficult to interpret. Immunohistochemical markers, such as AMACR, p63 and 34βE12 that are currently used in diagnosing prostate cancer, are of great value, but often their interpretation is ambiguous. In 2005 Tomlins et al. identified an emerging marker, erythroblastosis E26 rearrangement gene (ERG), which is a member of the family of genes encoding erythroblasttransformation specific transcription factors (ETS) with frequent expression in PC. Aim: The aim of this study was to investigate the expression of ERG in benign mimickers of PC in needle biopsies and its diagnostic value alone and in combination with AMACK and 34βE12. Results: Of the selected 46 biopsies, two were eventually diagnosed as PC Gleason score 6 as they were simultaneously ERG and AMACR-positive and 34βE12-negative. One case was considered atypical. The remaining 43 biopsies were diagnosed as benign cases: simple atrophy in 13 cases, partial atrophy in 11, adenosis in 9, basal cell hyperplasia in 3, post-atrophic hyperplasia in 3, clear cell hyperplasia in 2 and sclerotic adenosis in 2 cases. None of the 43 benign cores showed evidence of ERG expression. Conclusion: ERG could be preferably used in diagnosing prostate needle biopsies, lesions that are hard to interpret and controversial expression of AMACR/34βE12.
MATERIALS AND METHODS
Out of 1710 consecutive prostate needle biopsies diagnosed between January 2008 and December 2012 in our medical institution 46 cases were initially diagnosed as benign exhibiting architectural patterns for adenosis, atrophy and hyperplasia based on HE staining.
ImmunohIstochemIcal evaluatIon of eRG, amacR and 34βe12 Formalin-fixed paraffin-embedded prostate biopsy tissue samples were cut in 4-μm-thick sections. IHC was performed manually using monoclonal antibodies against ERG, AMACR and 34βE12. Antigen retrieval was performed in EDTA buffer (pH 6.0) for 40 min at 95ºC and then 10 min at room temperature. The slides were incubated with primary antibodies as follows: anti-ERG (1:200 dilution, clone ERP 3864, rabbit monoclonal antibody, Abcam), AMACR (ready for use, BSB 5395, mouse monoclonal antibody, BioSB) and 34βE12 (ready for use, BSB 5059, mouse monoclonal antibody, BioSB) for 90 min at room temperature. The IHC reaction was visualized with a peroxidase-based brown detection (Mouse/ Rabbit PolyDetector HRP/DAB System, BioSB). The slides were counterstained with hematoxylin. Simultaneously positive and negative IHC controls for the AMACR and 34βE12 were performed.
Only sections with positive endothelial ERG staining as an internal control were included. ERG expression was evaluated in suspected zones and considered positive if any nuclear staining was observed to vary from weak to strong. All cases were evaluated separately by 3 pathologists and the final diagnosis was rendered as benign, atypical or PC based on morphology and the results of IHC study.
statIstIcal analysIs All data were analyzed by descriptive and nonparametric analysis. Statistical analysis of antibodies sensitivity and specificity was performed by ROCcurve analysis. Statistical significance was accepted at p < 0.05. SPSS 19.0 was used in the analysis.
RESULTS
The mean age of the 46 men with initial diagnosis of benign prostatic tissue was 70 yrs (range, 52 to 83 yrs) and their mean pre-biopsy serum prostatespecific antigen level was 14.5 ng/mL (range 2. The only 2 ERG-positive cores were simultaneously AMACR-positive and 34βE12-negative so they were finally diagnosed as PC Gleason scored 6. One case was considered "atypical" due to positive expression of the two markers AMACR and 34βE12, but negative ERG staining and sufficient architectural and cellular criteria for PC.
The remaining 43 biopsies were diagnosed as benign exhibiting simple atrophy in 13, partial atrophy in 11, adenosis in 9, basal cell hyperplasia in 3, post-atrophic hyperplasia in 3, clear cell hyperplasia in 2 and sclerotic adenosis in 2 cases (Fig. 1) . Among them AMACR demonstrated complete absence of expression in 27 (62.79%) and positive in 16 (37.21%) of the biopsies. Weak to 3 Previously published data confirmed by our results demonstrated that biopsies containing benign mimickers of PC are difficult for interpretation even with the assistance of routine IHC markers. Therefore, scientists initiated investigations of the diagnostic utility of ERG-antibody in workup of challenging biopsies containing small foci of high-grade PC, benign mimickers and "atypical glands suspicious for cancer". Shah et al. found that positive ERG expression contributed to the correct diagnosis in 28% of the cases. Moreover, they noted positive AMACR expression in 40% of noncancerous cases and negative ERG staining in all of them. 12 Cheng et al. investigated only needle biopsies presenting foci of adenosis and found no evidence of ERG expression in 55 out of 55 cases. 13 Undoubtedly, a tumor marker, which demonstrates better specificity for PC and is not expressed in benign glands, may add the diagnostic value of AMACR/34βE12 IHC cocktail for better identification of "atypical" lesions, including benign mimickers of PC. In this study, the utility of ERG has contributed in cases where both markers (AMACR/34βE12) showed positive expression in suspected glands (Fig. 2) . Positive staining of 34βE12 in the basal cells complemented by negative ERG expression proved the benign character of the lesion. Statistically, a combination ERG/34βE12 (AUC 0,981, SE 0,00873) showed a higher specificity and sensitivity than the combination AMACR/34βE12 (AUC 0.950, SE 0.0174, p = 0.017) (Fig. 3) . 
DISCUSSION
This is the first study investigating ERG expression in benign prostatic tissue of a population of Bulgarian men. We evaluated 46 prostate needle biopsies exhibiting histological patterns of benign mimicker of PC. Of 46 cases, after final consensus 43 were diagnosed as benign and none of the 43 showed evidence of ERG expression. Our results are consistent with previous studies reporting ERG staining as highly specific for PC and its exceedingly rare appearance in the benign glands. Tomlins et al. identified ERG expression in only 2 of 162 cores (1%) diagnosed as benign. 8 In the series of 65 benign biopsies He et al. found nuclear ERG staining in 1 morphologically benign gland. 9 Van Leenders et al. detected weak ERG expression in 5 benign glands in a set of 87 needle biopsies. 10 The researchers reported that ERG-positive benign glands were located adjusted to or in between the neoplastic glands. They also suggested that there is a possibility of undersampled ERG-positive cancer presented in close proximity to the ERG-positive benign glands.
The present study found that 2.69% of the biopsies demonstrated cellular and architectural patterns of PC which are not sufficient for definitive diagnosis. Previous studies reported partial atrophy, simple atrophy and adenosis as the most frequent benign lesions that caused difficulty for pathologists. 3, 11 In our series the majority of benign In summary, this is the first study that investigated ERG expression in benign prostatic tissue in a Bulgarian population and all 43 biopsies diagnosed as benign showed no evidence of ERG expression. Although routine IHC cocktail was able to resolve 29 (63.04%) of the cases, ERG expression assisted in cores where both markers (AMACR/34βE12) were positive in suspected glands. We conclude that ERG could be preferably used in diagnosing prostate needle biopsies, lesions that are hard to interpret and controversial expression of AMACR/34βE12.
